World Cancer Day, 2020!

 

 

world-cancer-day--1200x630

 

Bentham Science publish Articles related to World Cancer Day in its SUBSCRIPTION BASED JOURNALS including:

 

 

For Books, please find the link here consisting of all the relevant eBooks and AVAIL 30% DISCOUNT OFFER on related books!

Testimonial By Dr. Bo-Shen Gong

Read what our Authors have to say about publishing in our Journal

Bo shen-01.jpg

Journal Name: Current Cancer Drug Targets

Contributed Article: Nanotherapy Targeting the Tumor Microenvironment

Wishing you a very Happy Birthday | Dr. Ruiwen Zhang

 

Dr. Ruiwen Zhang.jpg

 

Dr. Ruiwen Zhang

EDITOR-IN-CHIEF: Current Cancer Drug Targets

Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
USA

Press Release | Bentham Science journals improve impact factor ratings in 2019

 

The latest edition of Journal Citation Reports® 2019 has been published recently, and according to the report, Bentham Science Publishers (BSP) journals have significantly improved their Impact Factors. Current Neuropharmacology is leading the list again with the highest impact factor (IF: 4.568) among all the journals. In total, 40 BSP journals have received Impact Factor ratings this year. The latest results in the JCR 2019 reflect the high quality of research published by Bentham Science.

Journal Citation Reports (JCR) is an annual publication by Clarivate Analytics. JCR has been integrated with the Web of Science and is accessible from the Web of Science-Core Collections. Its purpose is to offer a systematic means to critically evaluate the world’s leading journals, with quantifiable, statistical information based on citation data.

Bentham Science publishes over 100 print & online scholarly subscription journals and books. Learn more about Bentham Science here: http://www.benthamscience.com

 

Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2019-06/bsp-bsl062019.php

Editors Choice Article | EH-42: A Novel Small Molecule Induces Apoptosis and Inhibits Migration and Invasion of Human Hepatoma Cells through Suppressing STAT3 Signaling Pathway

Journal Name: Current Cancer Drug Targets

Author(s): Qi-Zhe Gong, Di Xiao, Gui-Yi Gong, Jian Xu, Xiao-Dong Wen*, Feng Feng*, Wei Qu*.

 

 

Background: Since signal transducer and activator of transcription 3 (STAT3) is aberrantly activated in hepatocellular carcinoma (HCC) and plays a key role in this tumor progression. Inhibition of the STAT3 signaling pathway has been considered as an effective therapeutic strategy for suppressing HCC development.

Objective: In this study, we investigated the anti-cancer effects of EH-42 on HCC cells and tried to explain the underlying mechanism.

Methods: MTT assay, colon formation assay and AnnexinV-FITC/PI double-staining assay were performed to assess the effects of EH-42 on cell growth and survival. Wound healing assay and transwell invasion assay were performed to assess the effects of EH-42 on cell migration and invasion. Western blotting assay was performed to analyze the effects of EH-42 on relative proteins.

Results: According to the MTT assay, colon formation assay and AnnexinV-FITC/PI doublestaining assay, EH-42 could suppress the growth and induce apoptosis of HCC cells in a dosedependent manner. Further western blotting assay showed that the inhibitory effects of EH-42 on cell growth and survival were caused by activating caspase 3/9, suppressing the phospho-STAT3 (Tyr 705) and downregulating anti-apoptotic proteins like Bcl-2/Bcl-xL. Moreover, migration and invasion abilities of HCC cells were also inhibited by EH-42 in the wound healing assay and transwell invasion assay. The potential mechanism was that EH-42 could inhibit HCC metastasis via reversing epithelial-mesenchymal transition and downregulating the secretion of MMPs.

Conclusion: Taken together, these findings suggested that EH-42 could be a potential therapeutic agent for HCC treatment. To read out more, please visit: http://www.eurekaselect.com/168569/article

The Queensland University of Technology | Inhaled nanoparticles could treat lung cancer

 

Lung cancer sufferers could one day inhale targeted chemotherapy via chitosan nanoparticles, replacing intravenous and oral delivery with a non-invasive, lower dose and better uptake by the body method.

  • Delivering drugs via an inhaler into the lungs is the subject of research around the world
  • Dry powder inhalation of drugs promises a non-invasive, lower dose and better absorption method
  • Chitosan, made from crustacean shells, is biodegradable and is being investigated as a carrier for chemotherapy for lung cancer

https://www.qut.edu.au/news?id=142188

 

QUT pharmaceutical scientist Dr Nazrul Islam, from School of Clinical Sciences, said lung cancer was one of the most common cancers globally and one of the deadliest, being a leading cause of cancer deaths.

He said chitosan had long been investigated for drug delivery and medical applications. It is made from refined crustacean (prawns, crabs, lobster) shells and was an abundant and cheap polymer.

 “Drug delivery directly into the lungs via an inhaler is an efficient way to achieve local and systemic effects of medications,” Dr Islam said.

 

 

“My research is concerned with dry powder inhalation using chitosan nanoparticles loaded with drugs that can reach the lower respiratory tract and from there diffuse into the bloodstream.

“Chitosan is a natural polymer that is known as biodegradable and biocompatible (ie human-cell friendly) and has low toxicity and it can be bound with therapeutic drugs and made into nanoparticles.

“We use different chemical agents called cross-linkers to help form chitosan nanoparticles in which we incorporate drugs, and our concern is whether chitosan nanoparticles formed with some cross-linkers are biodegradable or not.

 “As yet, no studies have conclusively shown complete biodegradation or elimination of chitosan nanoparticles in lung tissue and my research is concerned with finding the form of chitosan that is able to biodegrade in the lungs’ unique tissues.”

Dr Islam said many scientists were investigating the delivery of chemotherapy drugs via the lungs.

 

 

“While many studies have looked at the use of lung delivery of drugs including chemotherapy, gene therapy, vaccines and immunotherapy, none, to my knowledge, has exclusively looked at chitosan as a safe carrier for lung drug delivery,” he said.

 “The reason we study chitosan is also because it has mucoadhesive properties which means it sticks to the lining of the lung cells and it has been found to improve the absorption of therapeutic agents by opening the junctions between cells of the lung lining to allow the drug to target cancer cells.

“Targeted delivery of drugs increases the target tissues’ exposure to the drug while reducing exposure of healthy cells and organs to that drug, which means less toxicity and fewer side-effects.”

Dr Islam said much research suggested chitosan-based nanoparticle drug delivery could be the way of the future to deliver drugs for many different conditions besides lung cancer.

 “We need more research to understand the real-life degradation of chitosan, and identify degradation products and their possible toxicities in the body before we can conduct human trials.

 

 

“We believe chitosan-based nanoparticulate drug delivery has the potential to deliver a large number of therapeutic agents to treat various diseases and open a new era for chitosan-based materials for lung drug delivery and other medical purposes.”

Inhaled micro/nanoparticulate anticancer drug formulations: An emerging targeted drug delivery strategy for lung cancers was published in Current Cancer Drug Targets.

 

 

New Issues of various Bentham Science Journals

 

1. Mini-Reviews in Medicinal Chemistry, Vol: 18, Issue: 16

https://bit.ly/2qCXROI

2. Mini-Reviews in Medicinal Chemistry, Vol: 18, Issue: 17

https://bit.ly/2qBcaDd

3. Current Drug Targets, Vol: 19, Issue: 13

https://bit.ly/2QttYLL

4. Current Drug Metabolism, Vol: 19, Issue: 10

https://bit.ly/2qAdypw

5. Current Cancer Drug Targets, Vol: 18, Issue: 8

https://bit.ly/2z3e6sN

6. Current Pharmaceutical Analysis, Vol: 14, Issue: 6

https://bit.ly/2PNXYVE

7. The Natural Products Journal, Vol: 8, Issue: 3

https://bit.ly/2yYGJY6

8. Current Organocatalysis, Vol: 5, Issue: 2

https://bit.ly/2RKY65t

9. Current Drug Safety, Vol: 13, Issue: 3

https://bit.ly/2OvKMjC

10. Current Topics in Medicinal Chemistry, Vol: 18, Issue: 12

https://bit.ly/2D9ecSA

 

Issues

New Issue :: Current Cancer Drug Targets (Volume: 18, Issue: 7)

 

Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.

Current Cancer Drug Targets publishes original research articles, letters, reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.

 

CCDT

 

Articles from the journal Current Cancer Drug Targets Volume 18, Issue 7:

 

For details on the articles, please visit this link ::  https://bit.ly/2M44plA

MOST ACCESSED ARTICLE – Multimodal HDAC Inhibitors with Improved Anticancer Activity – Current Cancer Drug Targets

Journal: Current Cancer Drug Targets

Author(s): Rainer Schobert, Bernhard Biersack

Graphical Abstract:

 

Abstract:

Histone deacetylases (HDACs) play a significant role in the proliferation and dissemination of cancer and represent promising epigenetic drug targets. The HDAC inhibitor vorinostat featuring a zinc-binding hydroxamate fragment was already clinically approved. However, HDAC inhibitors containing hydroxamic acids are often hampered by acquired or intrinsic drug resistance and may lead to enhanced tumor aggressiveness. In order to overcome these drawbacks of hydroxamate HDAC inhibitors, a series of multimodal derivatives of this compound class, including such with different zinc-binding groups, was recently developed and showed promising anticancer activity. This review provides an overview of the chemistry and pleiotropic anticancer modes of action of these conceptually new HDAC inhibitors.

Read more here: http://www.eurekaselect.com/149780/article

 

RECENTLY PUBLISHED ISSUES – BENTHAM SCIENCE JOURNALS

Current Bioactive Compounds 14-2

https://bit.ly/2sRuB8d

Current Topics in Medicinal Chemistry 18-5

https://bit.ly/2JvIWSg

Mini-Reviews in Medicinal Chemistry 18-11

https://bit.ly/2l7XtoF

Current Hypertension Reviews 14-1

https://bit.ly/2MgTgv0

Recent Innovations in Chemical Engineering 11-1

https://bit.ly/2HHqAI5

Current Cancer Drug Targets 18-6

https://bit.ly/2JO5e0P

RIA

%d bloggers like this: